Gene Therapy Strategies: Can We Eradicate HIV?

@article{Lunzen2011GeneTS,
  title={Gene Therapy Strategies: Can We Eradicate HIV?},
  author={Jan van Lunzen and Boris Fehse and Joachim Hauber},
  journal={Current HIV/AIDS Reports},
  year={2011},
  volume={8},
  pages={78-84}
}
Despite the tremendous advances in antiretroviral combination therapy over the last decade, eradication of HIV from the infected organism is still an elusive goal. Lifelong therapy is associated with potential long-term toxicity, adherence problems, and development of drug resistance. Thus, gene therapy approaches targeting viral eradication are still attractive. Here a number of studies have failed to show a clear clinical benefit yet. Current approaches were mainly limited by a low number of… 
Potential mechanisms for cell-based gene therapy to treat HIV/AIDS
TLDR
Hematopoietic stem cell-based gene therapy for HIV/AIDS may eventually become an alternative for standard ART and should ideally provide a functional cure in which the virus is durably controlled without medication.
Potential Strategies for an HIV Infection Cure
TLDR
Despite long-term viral suppression with antiretroviral therapy (ART), HIV persists in reservoirs and sanctuary sites, leading to problems of compliance, toxicity, and cost and new molecules intended to purge this reservoir or gene therapy approaches are warranted.
Excision of HIV-1 Proviral DNA by Recombinant Cell Permeable Tre-Recombinase
TLDR
E.coli expressed Tre-recombinases were able to translocate efficiently into cells and showed significant recombination activity on HIV-1 LTR sequences, providing the basis for the non-genetic transient application of engineered recombinases, which may be a valuable component of future HIV eradication strategies.
Eliminating the HIV Reservoir
TLDR
Recent findings on the biology of HIV persistence are reviewed and how HIV eradication trials should be designed in the near future are detailed.
Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model.
TLDR
Data suggest that hematopoietic stem cells protection may be a potential alternative to conventional antiretroviral therapy in patients with HIV/AIDS.
Highly Significant Antiviral Activity of HIV-1 LTR-Specific Tre-Recombinase in Humanized Mice
TLDR
The conditional expression of Tre-recombinase from an advanced lentiviral self-inactivation (SIN) vector in HIV-infected cells is reported, resulting in accurate provirus excision in the absence of cytopathic effects and pronounced Tre-mediated antiviral effects are demonstrated in vivo.
Development of Lentiviral Vectors Simultaneously Expressing Multiple siRNAs Against CCR5, vif and tat/rev Genes for an HIV-1 Gene Therapy Approach
TLDR
Results showed that the antiviral effect is influenced by different factors, including the promoter used to express the RNAi molecules and the selected cassette combination, which contribute to gain further insights in the design of RNAi-based gene therapy approaches against HIV-1 for clinical application.
Evolutionary decay and the prospects for long-term disease intervention using engineered insect vectors
  • J. Bull
  • Biology
    Evolution, medicine, and public health
  • 2015
TLDR
Old and new methods of population suppression are reviewed with an emphasis on the potential for evolution of resistance to these strategies, and properties of interventions that will be more or less effective in blocking resistance evolution are proposed.
Inhibition of HIV-1 Viral Infection by an Engineered CRISPR Csy4 RNA Endoribonuclease
TLDR
It is found that the trans-expressing VPR-Csy4 almost completely blocked viral infection in two target cell lines (SupT1, Ghost) and was a promising tool that could be tailored further to target HIV-1.
...
1
2
...

References

SHOWING 1-10 OF 55 REFERENCES
Genetic therapies against HIV
TLDR
Gene therapy offers the promise of preventing progressive HIV infection by sustained interference with viral replication in the absence of chronic chemotherapy, andGene-targeting strategies are being developed with RNA-based agents, and protein-basedagents, such as the mutant HIV Rev protein M10, fusion inhibitors and zinc-finger nucleases.
Gene Therapeutic Approaches for Immune Modulation in AIDS
TLDR
Strategies to improve the technologies and procedures involved in gene therapeutic immune reconstitution of AIDS patients are discussed.
Impact of gene-modified T cells on HIV infection dynamics.
Protection of Stem Cell-Derived Lymphocytes in a Primate AIDS Gene Therapy Model after In Vivo Selection
TLDR
The ability to select protected HSC-derived lymphocytes in vivo in a clinically relevant nonhuman primate model of HIV/SHIV infection is demonstrated and can be evaluated in human clinical trials in AIDS lymphoma patients.
Transfer of Autologous Gene-modified T Cells in HIV-infected Patients with Advanced Immunodeficiency and Drug-resistant Virus.
TLDR
The transfer of gene-modified cells was safe, led to sustained levels of gene marking, and may improve immune competence in HIV-infected patients with advanced disease and multidrug-resistant virus.
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.
TLDR
This study indicates that cell-delivered gene transfer is safe and biologically active in individuals with HIV and can be developed as a conventional therapeutic product.
Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation.
TLDR
Successful reconstitution of CD4(+) T cells at the systemic level as well as in the gut mucosal immune system after CCR5Δ32/Δ 32 stem cell transplantation is demonstrated, suggesting that cure of HIV has been achieved in this patient.
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies
TLDR
The current understanding of the molecular mechanisms involved in the establishment and maintenance of HIV-1 latency and in the transcriptional reactivation from latency are reviewed and the potential of new therapeutic strategies based on this understanding of latency are highlighted.
Gene therapy for HIV infection: what does it need to make it work?
TLDR
The determinants of therapeutic efficacy are focused on and the potential and also the limits of current gene therapy approaches for HIV infection are discussed.
How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection.
TLDR
Results from clinical trials indicate that approximately half of the treatment experienced patients will predominantly harbour C CR5 tropic quasispecies and will thus qualify for treatment with CCR5 antagonists and it is likely that maraviroc will be recommended in early stages of salvage therapy at present and might replace more inconvenient drugs like enfuvirtide in later lines of therapy.
...
1
2
3
4
5
...